Vertex Pharmaceuticals (VRTX -1.6%) is out with financial guidance ahead of its presentation at the JPMorgan Healthcare Conference on Tuesday.
Cash and equivalents as of FY13 end: $1.47B.
FY14 revenues seen at $570-600M versus consensus of $659.93B.
Kalydeco net revenues for FY14 projected at: $470-500M.
2014 projected opex: $900-950M. (PR)